Logo image of ZBIO

ZENAS BIOPHARMA INC (ZBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZBIO - US98937L1052 - Common Stock

19.825 USD
+0.23 (+1.2%)
Last: 1/22/2026, 1:17:10 PM
Fundamental Rating

2

ZBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. While ZBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. ZBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ZBIO has reported negative net income.
  • In the past year ZBIO has reported a negative cash flow from operations.
ZBIO Yearly Net Income VS EBIT VS OCF VS FCFZBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • ZBIO has a Return On Assets (-58.97%) which is in line with its industry peers.
  • ZBIO has a Return On Equity of -96.68%. This is comparable to the rest of the industry: ZBIO outperforms 47.24% of its industry peers.
Industry RankSector Rank
ROA -58.97%
ROE -96.68%
ROIC N/A
ROA(3y)-85.61%
ROA(5y)N/A
ROE(3y)-150.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZBIO Yearly ROA, ROE, ROICZBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ZBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZBIO Yearly Profit, Operating, Gross MarginsZBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

  • ZBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ZBIO has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for ZBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZBIO Yearly Shares OutstandingZBIO Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
ZBIO Yearly Total Debt VS Total AssetsZBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of 1.69, we must say that ZBIO is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.69, ZBIO is in the better half of the industry, outperforming 65.90% of the companies in the same industry.
  • ZBIO has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.37, ZBIO is doing worse than 69.14% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 1.69
ROIC/WACCN/A
WACC8.89%
ZBIO Yearly LT Debt VS Equity VS FCFZBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 5.66 indicates that ZBIO has no problem at all paying its short term obligations.
  • ZBIO has a Current ratio (5.66) which is comparable to the rest of the industry.
  • ZBIO has a Quick Ratio of 5.66. This indicates that ZBIO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ZBIO (5.66) is better than 61.33% of its industry peers.
Industry RankSector Rank
Current Ratio 5.66
Quick Ratio 5.66
ZBIO Yearly Current Assets VS Current LiabilitesZBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for ZBIO have decreased strongly by -296.61% in the last year.
  • Looking at the last year, ZBIO shows a very negative growth in Revenue. The Revenue has decreased by -90.00% in the last year.
EPS 1Y (TTM)-296.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.7%
Revenue 1Y (TTM)-90%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ZBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.94% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.58%
EPS Next 2Y19.22%
EPS Next 3Y13.28%
EPS Next 5Y10.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZBIO Yearly Revenue VS EstimatesZBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ZBIO Yearly EPS VS EstimatesZBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZBIO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZBIO Price Earnings VS Forward Price EarningsZBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZBIO Per share dataZBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ZBIO's earnings are expected to grow with 13.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.22%
EPS Next 3Y13.28%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ZBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ZENAS BIOPHARMA INC

NASDAQ:ZBIO (1/22/2026, 1:17:10 PM)

19.825

+0.23 (+1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-09
Inst Owners63.62%
Inst Owner Change0%
Ins Owners0.65%
Ins Owner Change1.8%
Market Cap1.06B
Revenue(TTM)15.00M
Net Income(TTM)-189.90M
Analysts88.57
Price Target41.57 (109.68%)
Short Float %12.07%
Short Ratio6.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.44%
Min EPS beat(2)-16.71%
Max EPS beat(2)-14.17%
EPS beat(4)1
Avg EPS beat(4)-73.08%
Min EPS beat(4)-290.79%
Max EPS beat(4)29.34%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.44%
PT rev (3m)25.66%
EPS NQ rev (1m)-117.8%
EPS NQ rev (3m)-39.07%
EPS NY rev (1m)0.16%
EPS NY rev (3m)-5.71%
Revenue NQ rev (1m)-39.47%
Revenue NQ rev (3m)283.33%
Revenue NY rev (1m)-30%
Revenue NY rev (3m)-16.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 70.95
P/FCF N/A
P/OCF N/A
P/B 5.42
P/tB 5.42
EV/EBITDA N/A
EPS(TTM)-7.26
EYN/A
EPS(NY)-4.32
Fwd EYN/A
FCF(TTM)-3.05
FCFYN/A
OCF(TTM)-2.95
OCFYN/A
SpS0.28
BVpS3.66
TBVpS3.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.97%
ROE -96.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.61%
ROA(5y)N/A
ROE(3y)-150.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6445.57%
Cap/Sales 33.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.66
Quick Ratio 5.66
Altman-Z 1.69
F-Score3
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)976.2%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-296.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.7%
EPS Next Y49.58%
EPS Next 2Y19.22%
EPS Next 3Y13.28%
EPS Next 5Y10.94%
Revenue 1Y (TTM)-90%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.62%
EBIT Next 3Y-21.49%
EBIT Next 5YN/A
FCF growth 1Y-390.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-391.3%
OCF growth 3YN/A
OCF growth 5YN/A

ZENAS BIOPHARMA INC / ZBIO FAQ

What is the fundamental rating for ZBIO stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZBIO.


What is the valuation status of ZENAS BIOPHARMA INC (ZBIO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ZENAS BIOPHARMA INC (ZBIO). This can be considered as Overvalued.


How profitable is ZENAS BIOPHARMA INC (ZBIO) stock?

ZENAS BIOPHARMA INC (ZBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for ZBIO stock?

The financial health rating of ZENAS BIOPHARMA INC (ZBIO) is 4 / 10.


Can you provide the expected EPS growth for ZBIO stock?

The Earnings per Share (EPS) of ZENAS BIOPHARMA INC (ZBIO) is expected to grow by 49.58% in the next year.